BioAtla, Inc. (BCAB) Income Statement
BCAB 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsBCAB revenue and net income
Where BCAB's revenue goes
2025Each bar shows an amount and its share of revenue. BCAB kept −2,980.3% of revenue as net income.
BCAB profit margins
BCAB growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −81.8% | — | +36.1% | — |
| Gross profit | −507.7% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BCAB quarterly EPS vs estimates
BioAtla beat the analyst EPS estimate in 6 of the last 7 quarters.
BCAB income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $11.0M | $0 | $0 | $250,000 | $429,000 | $5.2M | $10.6M |
| Cost of revenue | $43.1M | $925,000 | $1.2M | $1.2M | $58.3M | $19.9M | $25.9M | $26.3M |
| Gross profit | −$41.1M | $10.1M | −$1.2M | −$1.2M | −$58.0M | −$19.5M | −$20.7M | −$15.7M |
| Research & development | $43.6M | $63.1M | $103.7M | $79.3M | $58.3M | $19.9M | $25.9M | $26.3M |
| Sales, general & admin | $17.6M | $21.8M | $27.2M | $28.8M | $38.4M | $10.6M | $7.5M | $12.6M |
| Total operating expenses | $18.2M | $84.0M | $128.5M | $106.9M | $38.4M | $10.6M | $7.5M | $38.9M |
| Operating income | −$59.3M | −$73.9M | −$129.7M | −$108.1M | −$96.4M | −$30.1M | −$28.3M | −$28.2M |
| Interest income | $843,000 | $3.4M | $5.7M | $1.6M | $350,000 | $100,000 | $128,000 | $209,000 |
| Interest expense | — | — | — | $1.7M | $3,000 | $1.4M | $1.6M | $949,000 |
| Income before taxes | −$59.6M | −$69.8M | −$123.5M | −$106.5M | −$95.4M | −$35.9M | −$29.9M | −$29.0M |
| Income taxes | — | — | — | −$1.2M | $4,000 | $1.4M | $1.5M | $204,000 |
| Net income | −$59.6M | −$69.8M | −$123.5M | −$105.3M | −$95.4M | −$35.9M | −$29.8M | −$29.0M |
| EBITDA | −$59.2M | −$68.9M | −$122.2M | −$105.3M | −$94.1M | −$33.5M | −$27.4M | −$27.2M |
| EPS (diluted) | −$26.81 | −$57.30 | −$102.06 | −$106.13 | −$108.47 | −$2.33 | −$69.00 | — |
| Gross margin | −2,053.7% | 91.6% | — | — | −23,209.6% | −4,546.4% | −398.4% | −147.5% |
| Operating margin | −2,965.2% | −672.2% | — | — | −38,576.0% | −7,016.1% | −543.6% | −265.7% |
| Net margin | −2,980.3% | −634.3% | — | — | −38,160.8% | −8,357.3% | −573.0% | −272.7% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.5M | $0 | $2.0M | $0 | $0 | $0 | $0 | $11.0M | $0 | $0 | $1.7M | $0 |
| Cost of revenue | $0 | $120,000 | −$806,000 | $9.5M | $567,000 | $183,000 | $11.7M | $228,000 | $229,000 | $240,000 | $368,000 | $270,000 |
| Gross profit | $6.5M | −$120,000 | $2.0M | −$9.5M | −$567,000 | −$183,000 | −$11.7M | $11.0M | −$229,000 | −$240,000 | −$368,000 | −$270,000 |
| Research & development | $3.3M | $4.6M | $8.0M | $9.5M | $13.7M | $12.4M | $11.7M | $16.4M | $16.2M | $18.9M | $22.7M | $28.4M |
| Sales, general & admin | $2.9M | $4.7M | $3.3M | $4.2M | $5.0M | $5.3M | $4.6M | $5.9M | $6.0M | $5.8M | $5.9M | $6.6M |
| Total operating expenses | $6.3M | $9.3M | $11.3M | $13.8M | $18.6M | $17.6M | $16.2M | $22.3M | $22.0M | $24.2M | $28.2M | $34.8M |
| Operating income | $227,000 | −$9.3M | −$9.3M | −$13.8M | −$18.6M | −$17.6M | −$16.2M | −$11.3M | −$22.0M | −$24.5M | −$28.5M | −$35.0M |
| Interest income | $16,000 | $37,000 | $73,000 | $133,000 | $233,000 | $400,000 | $554,000 | $692,000 | $900,000 | $1.2M | $1.6M | $1.7M |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $1.5M | — |
| Income before taxes | $452,000 | −$6.3M | −$9.8M | −$15.8M | −$18.7M | −$15.3M | −$14.9M | −$10.6M | −$21.1M | −$23.2M | −$26.9M | −$33.3M |
| Income taxes | — | — | — | — | — | — | — | — | — | $196,724 | $4.9M | −$2.0M |
| Net income | $452,000 | −$6.3M | −$9.8M | −$15.8M | −$18.7M | −$15.3M | −$14.9M | −$10.6M | −$21.1M | −$23.2M | −$26.9M | −$33.3M |
| EBITDA | $18,000 | −$6.2M | −$9.8M | −$15.8M | −$18.6M | −$15.2M | −$14.7M | −$10.4M | −$20.8M | −$23.0M | −$26.6M | −$33.1M |
| EPS (diluted) | $0.14 | −$4.22 | $0.00 | −$13.50 | −$0.31 | −$13.00 | −$0.30 | −$11.00 | −$22.00 | −$24.00 | −$0.56 | −$35.00 |
| Gross margin | 100.0% | — | 100.0% | — | — | — | — | 100.0% | — | — | −21.6% | — |
| Operating margin | 3.5% | — | −462.8% | — | — | — | — | −102.5% | — | — | −1,672.7% | — |
| Net margin | 7.0% | — | −489.2% | — | — | — | — | −96.2% | — | — | −1,578.3% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BCAB's financial statements (latest annual report filed March 31, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BCAB financial results
In fiscal year 2025 (ended December 31, 2025), BioAtla reported revenue of $2.0 million, down 81.8% from the year before. It had a net loss of $59.6 million, a net profit margin of −2,980.3%. Diluted earnings per share came to −$26.81. Over five years revenue grew at an average rate of 36.1% a year.
See the BCAB stock overview for the latest quote and news, or the BCAB chart for price history and technical indicators.
BCAB income statement FAQ
What is BioAtla's annual revenue?
BioAtla reported total revenue of $2.0 million for fiscal year 2025, which ended on December 31, 2025. That was down 81.8% from $11.0 million the previous year.
Is BioAtla profitable?
No. BioAtla reported a net loss of $59.6 million in fiscal 2025, a net profit margin of −2,980.3%; its operating margin was −2,965.2%.
What is BioAtla's gross margin?
BioAtla's gross margin was −2,053.7% in fiscal 2025: for every $100 of revenue, BioAtla kept $-2054 after the direct cost of its products and services.
How much does BioAtla spend on research and development?
BioAtla spent $43.6 million on research and development in fiscal 2025, 2,178.7% of revenue.
How fast is BioAtla growing?
Revenue grew 36.1% a year on average over the last five fiscal years, from $0.4 million to $2.0 million.
What are BioAtla's earnings per share?
BioAtla earned $-26.81 per diluted share in fiscal 2025, compared with $-57.30 a year earlier.
When does BioAtla's fiscal year end?
BioAtla's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 31, 2026.